GO
Loading...

Pharmaceuticals

More

  • NEW YORK— Pharmaceutical giant Actavis to buy Botox maker Allergan for $66 billion in cash-and-stock.

  • Study lifts cloud over heart drugs Zetia, Vytorin Monday, 17 Nov 2014 | 8:53 AM ET

    CHICAGO— A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. Merck& Co.' s ezetimibe, which went on sale in 2002, lowers cholesterol in a different way. The drug won Food and Drug Administration approval for lowering LDL, but some studies suggested that might not translate to fewer heart attacks and strokes.

  • Ahead of the Bell: Allergan soars on deal reports Monday, 17 Nov 2014 | 7:38 AM ET

    Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the Botox maker, which is fighting off a separate takeover bid from Valeant Pharmaceuticals. The New York Times reported that Allergan is nearing a deal to sell itself to Actavis for more than $62.5...

  • *GlaxoSmithKline again leads index for best drug access. The contradictory advances and the problems facing the industry are evident at GlaxoSmithKline, which retained its long-standing top spot in the index, while simultaneously featuring in a major bribery scandal in China. "Corruption is terrible, but it also takes attention away from the fact that these...

  • Actavis nears rescue bid for Allergan: Sources Sunday, 16 Nov 2014 | 2:52 PM ET

    Actavis is nearing a deal to acquire Allergan in a cash and stock deal worth more than $210 per Allergan share, sources tell CNBC.

  • FDA approves Lemtrada for multiple sclerosis Saturday, 15 Nov 2014 | 1:00 PM ET

    NEW YORK— The Food and Drug Administration has approved Lemtrada, a treatment for relapsing multiple sclerosis made by the drugmaker Genzyme. Sanofi, the parent company of Genzyme, wants to market Lemtrada as a treatment for relapsing multiple sclerosis, a disease in which the immune system attacks healthy nerves. Sanofi estimates that the disease affects...

  • Intercept Pharmaceuticals CEO Mark Pruzanski, provides insight to his company's efforts to tackle NASH, or nonalcoholic steatohepatitis, saying over 10 percent of the U.S. population is thought to have NASH. Pruzanski also weighs in on being a public company.

  • FDA approves Roche's Avastin for ovarian cancer Friday, 14 Nov 2014 | 3:14 PM ET

    NEW YORK— Swiss drugmaker Roche said Friday that the Food and Drug Administration approved its drug Avastin as a treatment for ovarian cancer. Roche said the FDA approved Avastin in combination with chemotherapy as a treatment for recurrent cases of cancer that are resistant to platinum-based chemotherapy. Roche reported $6.25 billion in revenue from the...

  • LONDON, Nov 14- Pfizer appears unlikely to make a fresh bid for AstraZeneca in 12 days time, when an enforced cooling-off period ends, and the U.S. drugmaker is now weighing other less risky targets. People with direct knowledge of the situation said Pfizer has been reviewing different takeover scenarios with a U.S. investment bank ahead of Nov. 26, when it is allowed...

  • World Bank: Ebola fund would create incentives Friday, 14 Nov 2014 | 5:12 AM ET

    BRISBANE, Australia— A proposed global emergency fund to contain the next Ebola outbreak would also provide an incentive for drug companies to develop vaccines to fight other future pandemics, World Bank President Jim Yong Kim said Friday. The Ebola outbreak is the worst ever and has infected some 9,900 people and killed more than 4,800 in the hardest hit...

  • Mallinckrodt shares slide as FDA reclassifies drug Thursday, 13 Nov 2014 | 2:45 PM ET

    Mallinckrodt will re-evaluate its fiscal 2015 forecast after the Food and Drug Administration said it is concerned that the company's generic ADHD drug is not equivalent to the brand-name drug it is based on. The FDA is reclassifying Mallinckrodt's drug, methylphenidate ER, and another generic made by Kudco Ireland Ltd. The agency will no longer recommend...

  • LONDON, Nov 13- Apollo Global Management is planning to bid for all GlaxoSmithKline's mature drugs, joining an auction expected to value the business at more than $3 billion, according to four people familiar with the process. GSK, Britain's biggest drugmaker, is looking to divest its mature prescription medicine products sold in North America and western...

  • UK doctors to 'prescribe' health apps Thursday, 13 Nov 2014 | 8:31 AM ET

    UK patients could soon be "prescribed" a smartphone application instead of a medical prescription when visiting their doctor.

  • But a series of failed deals, including the collapse of a $55 billion tie-up between UK drugmaker Shire and U.S. peer AbbVie, has led to losses for some of the world's biggest proponents of the strategy, with investors pulling out $3.3 billion in the last two months alone. "The AbbVie/ Shire break, in particular, has led to a far reaching de-risking exercise for many...

  • Why plastic bottles could be bad for your health Wednesday, 12 Nov 2014 | 10:45 AM ET

    Experts are meeting in Brussels to debate whether some materials like plastic bottles could be dangerous.

  • Nov 11- AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat. AbbVie said on Tuesday 100 percent of the patients who were given the drug and had failed previous treatment showed high response rates at 12 weeks after the treatment.

  • Lots of risk in biotech: Pro     Monday, 10 Nov 2014 | 2:22 PM ET

    Discussing warning signs from Dendreon, and other worrisome companies, with Les Funtleyder, E Square Asset Management.

  • Dendreon declares bankruptcy     Monday, 10 Nov 2014 | 2:18 PM ET

    Joseph Pantginis, Roth Capital, has been negative on Dendreon for a long time, ahead of the drugmaker's bankruptcy protection filing.

  • Hepatitis B next great challenge: Arrowhead     Monday, 10 Nov 2014 | 1:11 PM ET

    Chris Anzalone, Arrowhead CEO, discusses current studies on the hepatitis B virus and its effect on the liver, and whether the company is gaining the confidence back of shareholders.

  • Nov 10- Cancer vaccine maker Dendreon Corp filed for Chapter 11 bankruptcy protection on Monday after its potential blockbuster cancer drug failed to live up to expectations, saddling the company with heavy debt. Dendreon's stock was down nearly 62 percent at 36 cents in premarket trading. Under the agreements, senior noteholders will support a plan of...